On December 9, 2022, the 2022 China Pharmaceutical R&D Strength Ranking series of lists was announced at the "2022 Conference on High Quality Development of the Health Industry and the 7th China Pharmaceutical R&D Innovation Summit (PDI)". Among hundreds of biopharmaceutical companies, Laviana Pharma was awarded the title of "Top 20 China Pharmaceutical CDMO in 2022".

The conference released the 2022 China R&D Strength Ranking and Top 20 China Pharmaceutical CDMO in 2022, and Laviana Pharma was awarded as "Top 20 China Pharmaceutical CDMO in 2022", which is the first time for Laviana Pharma to be selected for this award and a high recognition of Laviana Pharma's CDMO service achievements.

These awarded enterprises were jointly selected by yaozh.com, China Pharmaceutical R&D Summit Organizing Committee and China Pharmaceuticals, which are both authoritative and influential. The selection was based on big data and enterprise scale, and the participating CDMO companies were screened and ranked in multiple dimensions from 10 indicators: annual total revenue and growth, net profit and growth, R&D investment and growth, staff size and growth, brand awareness, and segment influence.

In 2022, Laviana Pharma's revenue grew 64% year-on-year and its employees grew 50% year-on-year, including the expansion of R&D staff to more than 200, with 30% of professional staff with master's degree or above. In addition, Laviana Pharma continues to invest in production construction and actively explores the downstream industry value chain. The GMP production base in Cangzhou will be completed and put into use in the first quarter of 2023, which marks the further improvement of Laviana Pharma's comprehensive service capability to drive growth in the competitive market.

Founded nearly two decades ago, Laviana Pharma has been widely recognized by innovative pharmaceutical companies both at home and abroad. Following the corporate mission of "changing the world with art of chemistry", Laviana Pharma actively explores and extends services to the downstream industry value chain. By building a platform for innovative process research and manufacture outsourcing, we provide more one-stop comprehensive services for innovative pharmaceutical companies.

About Laviana Pharma

Founded in 2003, Laviana Pharma is a technology-driven, innovative pharmaceutical contract development and manufacturing organization (CDMO). Our main services cover the whole process of pharmacy services (CMC) from laboratory to commercialization of small molecule innovative drugs, including: process research, pilot production and commercial production services for APIs, registered starting materials and pharmaceutical intermediates from pre-clinical to market, as well as approval services during the development process. We are now the home to: R&D center - Laviana Pharma (Tianjin), GMP production base - Laviana Pharma (Cangzhou), commercial production base of pharmaceutical intermediates - Laviana Pharma (Taizhou) and 3 business centers in Beijing, Shanghai and overseas market.